Invest in Israel Newsletter March 2010 Edition
VC Cafe
APRIL 8, 2010
Israel’s central bank, Morgan Stanley and other financial institutions have forecasted 3.5% US drug powerhouse Pfizer and Iceland-based Actavis were among the bidders in the final round, but Teva beat their offers. The deal is expected to capture significant synergies for Teva.
Let's personalize your content